Table 2.
Coagulation‐related laboratory results
| Unit | Normal range | ||
|---|---|---|---|
| D‐dimer |
0.5 (day 0) 2.5 (day 15) 0.6 (day 32) |
μg/mL | 0–0.90 |
| Fibrin/fibrinogen degradation products (FDP) |
≦2.5 (day 0) 5.9 (day 15) ≦2.5 (day 32) |
μg/mL | 0–4.90 |
| Protein C activity |
46 (day 16) 49 (day 33) |
% | 64–135 |
| Protein C antigen | 41 (day 33) | % | 70–150 |
| von Willebrand factor antigen |
≧201 (day 16) ≧201 (day 33) |
% | 50–150 |
| von Willebrand factor activity |
196 (day 16) 163 (day 33) |
% | 50–150 |
| Protein S antigen | 89 | % | 74–132 |
| PT | 83.3 | % | 70.10≦ |
| PT‐INR | 1.08 | INR | ≦1.15 |
| APTT | 34.4 | s | 29.6–40.8 |
| Thrombin‐antithrombin III complex | 3.9 | ng/mL | ≦3.0 |
| Prothrombin fragment F1 + 2 | 194 | pmol/L | 69–229 |
| Antithrombin III | 109 | % | 80–130 |
| Factor II activity | 107 | % | 74–146 |
| Factor X activity | 91 | % | 71–128 |
| Factor XIII antigen | 102 | % | 70–999 |
| Plasminogen | 88 | % | 80–130 |
| Antinuclear antibody | ≦1:40 | Titer | 0–1:79 |
| Anti‐cardiolipin antibody | 1 | U/mL | 0–9.9 |
| Anti‐cardiolipin β2‐glycoprotein I complex antibody | ≦1.3 | U/mL | 0–3.40 |
| Lupus anticoagulant | 1 | s | 0–1.30 |